The role and efficacy of Tafasitamab

Tafasitamab (Tafasitamab) is a CD19-targeted immunotherapy designed to treat B-cell malignancies. Tafaracetam works as an immunotherapy through direct cytotoxicity and binding to cells of the immune system, where it attacks and destroys malignant B cells. B cells, also known as B lymphocytes, play an important role in the body's immune system by producing antibodies against pathogens such as viruses and bacteria. CD19 is widely expressed in most stages of B cell development and in most B cell malignancies.

Tafaracetamumab binds to the antigenCD19, which is widely and uniformly expressed in different B-cell malignancies. Tafracetamab is engineered with an enhanced ability to bind to two types of immune system cells, natural killer (NK) cells and macrophages, which in turn can attack malignant B cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). In addition to direct cytotoxicity, lenalidomide has been shown to activate NK cells and increase NK cell numbers. The combination of tafracetamumab and lenalidomide enhances antitumor activity by synergistically activating NK cells (both) and macrophages (tafracetamumab).

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.